Craniopharyngioma—An update on metabolic and cognitive complications and new therapy
(2023) In Journal of Internal Medicine 294(3). p.269-280- Abstract
- Craniopharyngiomas (CPs) are rare primary brain epithelial tumors arising in the suprasellar region from remnants of Rathke's pouch. About 50% originate at the level of the third ventricle floor, including the hypothalamus (HT). CPs are characterized by a low proliferation rate and symptoms due to mass effect and local infiltration and are managed primarily with surgery and radiotherapy. Gross total removal of a CP will reduce the recurrence rate but increases the risk of HT damage. Today, subtotal resection is the goal and will reduce the risk of HT damage. There are two histological subtypes of CP—adamantinomatous (ACP) and papillary CP (PCP)—that differ in their genesis and age distribution. ACPs are driven by somatic mutations in... (More)
- Craniopharyngiomas (CPs) are rare primary brain epithelial tumors arising in the suprasellar region from remnants of Rathke's pouch. About 50% originate at the level of the third ventricle floor, including the hypothalamus (HT). CPs are characterized by a low proliferation rate and symptoms due to mass effect and local infiltration and are managed primarily with surgery and radiotherapy. Gross total removal of a CP will reduce the recurrence rate but increases the risk of HT damage. Today, subtotal resection is the goal and will reduce the risk of HT damage. There are two histological subtypes of CP—adamantinomatous (ACP) and papillary CP (PCP)—that differ in their genesis and age distribution. ACPs are driven by somatic mutations in CTNNB1 gene (encoding β-catenin), and PCPs frequently harbor somatic BRAF V600E mutations. There are also two phenotypes of outcome, the one with a rather good outcome without HT damage and the other with HT damage where recurrent operation with additional cranial radiotherapy results in HT obesity (HO), affecting psychosocial life and cognitive dysfunction. The group with HO suffers from metabolic syndrome, lower basal metabolic rate, and leptin and insulin resistances. There is currently no successful treatment for HO. The group with HT damage suffers from cognitive dysfunction with attention deficits, impaired episodic memory, and processing speed. Diffusion tensor imaging has shown significant microstructural white matter alteration in several areas important for cognition. Recently, complete or partial tumor response was shown to targeted therapy, with BRAF and Mekinist inhibitors for PCPs with BRAF V600E mutation. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4b2b7627-e25c-4078-9ce2-bc41f8ef89c5
- author
- Erfurth, Eva marie LU
- publishing date
- 2023-09-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Internal Medicine
- volume
- 294
- issue
- 3
- pages
- 269 - 280
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:37424210
- scopus:85164576885
- ISSN
- 1365-2796
- DOI
- 10.1111/joim.13684
- language
- English
- LU publication?
- no
- id
- 4b2b7627-e25c-4078-9ce2-bc41f8ef89c5
- date added to LUP
- 2023-11-13 11:18:38
- date last changed
- 2023-11-14 04:09:13
@article{4b2b7627-e25c-4078-9ce2-bc41f8ef89c5,
abstract = {{Craniopharyngiomas (CPs) are rare primary brain epithelial tumors arising in the suprasellar region from remnants of Rathke's pouch. About 50% originate at the level of the third ventricle floor, including the hypothalamus (HT). CPs are characterized by a low proliferation rate and symptoms due to mass effect and local infiltration and are managed primarily with surgery and radiotherapy. Gross total removal of a CP will reduce the recurrence rate but increases the risk of HT damage. Today, subtotal resection is the goal and will reduce the risk of HT damage. There are two histological subtypes of CP—adamantinomatous (ACP) and papillary CP (PCP)—that differ in their genesis and age distribution. ACPs are driven by somatic mutations in CTNNB1 gene (encoding β-catenin), and PCPs frequently harbor somatic BRAF V600E mutations. There are also two phenotypes of outcome, the one with a rather good outcome without HT damage and the other with HT damage where recurrent operation with additional cranial radiotherapy results in HT obesity (HO), affecting psychosocial life and cognitive dysfunction. The group with HO suffers from metabolic syndrome, lower basal metabolic rate, and leptin and insulin resistances. There is currently no successful treatment for HO. The group with HT damage suffers from cognitive dysfunction with attention deficits, impaired episodic memory, and processing speed. Diffusion tensor imaging has shown significant microstructural white matter alteration in several areas important for cognition. Recently, complete or partial tumor response was shown to targeted therapy, with BRAF and Mekinist inhibitors for PCPs with BRAF V600E mutation.}},
author = {{Erfurth, Eva marie}},
issn = {{1365-2796}},
language = {{eng}},
month = {{09}},
number = {{3}},
pages = {{269--280}},
publisher = {{Wiley-Blackwell}},
series = {{Journal of Internal Medicine}},
title = {{Craniopharyngioma—An update on metabolic and cognitive complications and new therapy}},
url = {{http://dx.doi.org/10.1111/joim.13684}},
doi = {{10.1111/joim.13684}},
volume = {{294}},
year = {{2023}},
}